Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 2
2005 1
2011 2
2012 1
2015 1
2016 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
Rodbard HW, Cariou B, Pieber TR, Endahl LA, Zacho J, Cooper JG. Rodbard HW, et al. Among authors: endahl la. Diabetes Obes Metab. 2016 Mar;18(3):274-80. doi: 10.1111/dom.12609. Epub 2016 Jan 11. Diabetes Obes Metab. 2016. PMID: 26592732 Free PMC article. Clinical Trial.
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Garber AJ, et al. Among authors: endahl la. Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0. Lancet. 2012. PMID: 22521072 Clinical Trial.
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF. Birkeland KI, et al. Among authors: endahl la. Diabetes Care. 2011 Mar;34(3):661-5. doi: 10.2337/dc10-1925. Epub 2011 Jan 26. Diabetes Care. 2011. PMID: 21270174 Free PMC article. Clinical Trial.
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.
Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C. Zinman B, et al. Among authors: endahl la. Lancet. 2011 Mar 12;377(9769):924-31. doi: 10.1016/S0140-6736(10)62305-7. Lancet. 2011. PMID: 21396703 Clinical Trial.
[Evaluation of surgical interventions in Denmark].
Utzon J, Olsen PS, Bay-Nielsen M, Andersen KB, Christensen B, Endahl LA, Krarup T, Lucht U, Ottesen BS, Schroeder TV, Kehlet H. Utzon J, et al. Among authors: endahl la. Ugeskr Laeger. 2001 Oct 8;163(41):5662-4. Ugeskr Laeger. 2001. PMID: 11665468 Danish. No abstract available.